Evidence map›Paper›PMID 40753540›Full record

ArticleJournal of cellular and molecular medicine2025

MARCH5 Promotes Cardiac Hypertrophy by Regulating Akt/mTOR/Gsk-3β/GATA4 Signalling Pathway.

Guoyong Li, Fengming Wu, Fan Lei, Jialiang Zhang, Yanbiao Liao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Red Araça (Biomedicines · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guoyong LiDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Fengming WuDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0009-0005-1430-3699
Fan LeiDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Jialiang ZhangDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Yanbiao LiaoDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-9853-0012

Funding

National Natural Science Foundation of China 81900348Sichuan Science and Technology Program 2023NSFSC1645Sichuan Science and Technology Program 2023NSFSC1650
6 · The paper itself

Abstract

This study aims to elucidate the role of MARCH5 in cardiac hypertrophy, thereby providing a theoretical foundation for novel therapeutic strategies for cardiac hypertrophy and heart failure. The expression of MARCH5 in cardiac hypertrophy models was assessed using immunohistochemistry, western blot (WB) and RT-qPCR. Gain- and loss-of-function experiments of MARCH5 in cardiac hypertrophy were conducted both in vitro and in vivo. WB, RT-qPCR, co-immunoprecipitation (CoIP), immunohistochemistry and immunofluorescence were performed to investigate the molecular mechanisms of MARCH5. MARCH5 expression was upregulated in hypertrophied myocardium. Ang II stimulation resulted in increased expression of MYH7, BNP and cardiomyocyte area. These effects were aggravated by MARCH5 overexpression but antagonised by MARCH5 knockdown. MARCH5 heterozygous (MARCH5

Indexed as

CardiomegalyGATA4 Transcription FactorGlycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMyocytes, CardiacGata4 protein, mouseGATA4 Transcription FactorGlycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasescardiac hypertrophyE3 ubiquitin ligaseheart failureMARCH5protein kinase Bubiquitin‐proteasome system

Identifiers

PMID40753540
PMCPMC12318481

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.